Insider Trading Alert - IPXL, TUP And MMS Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 14, 2014, 169 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $109.00 to $76,434,960.75.

Highlighted Stocks Traded by Insiders:

Impax Laboratories (IPXL) - FREE Research Report

Terreri Peter R, who is Director at Impax Laboratories, sold 666 shares at $26.70 on May 14, 2014. Following this transaction, the Director owned 41,336 shares meaning that the stake was reduced by 1.59% with the 666-share transaction.

The shares most recently traded at $25.01, down $1.69, or 6.76% since the insider transaction. Historical insider transactions for Impax Laboratories go as follows:

  • 4-Week # shares sold: 224,719
  • 12-Week # shares sold: 228,719
  • 24-Week # shares sold: 231,719

The average volume for Impax Laboratories has been 800,700 shares per day over the past 30 days. Impax Laboratories has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 0.4% year-to-date as of the close of trading on Wednesday.

Impax Laboratories, Inc., a specialty pharmaceutical company, develops, manufactures, and markets bioequivalent pharmaceutical products; and develops and markets branded products. The company operates through two segments, Global Pharmaceuticals Division and Impax Pharmaceutical Division. The company has a P/E ratio of 2593.0. Currently, there are 2 analysts who rate Impax Laboratories a buy, 2 analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IPXL - FREE

TheStreet Quant Ratings rates Impax Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Impax Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Tupperware Brands (TUP) - FREE Research Report

Gupta Asha, who is Group President at Tupperware Brands, sold 1,108 shares at $85.25 on May 14, 2014. Following this transaction, the Group President owned 17,917 shares meaning that the stake was reduced by 5.82% with the 1,108-share transaction.

The shares most recently traded at $83.30, down $1.95, or 2.34% since the insider transaction. Historical insider transactions for Tupperware Brands go as follows:

  • 4-Week # shares sold: 47,774
  • 12-Week # shares sold: 52,274
  • 24-Week # shares sold: 88,020

The average volume for Tupperware Brands has been 497,800 shares per day over the past 30 days. Tupperware Brands has a market cap of $4.3 billion and is part of the consumer goods sector and consumer non-durables industry. Shares are down 10.59% year-to-date as of the close of trading on Wednesday.

Tupperware Brands Corporation operates as a direct-to-consumer marketer of various products across a range of brands and categories worldwide. The stock currently has a dividend yield of 3.18%. The company has a P/E ratio of 16.6. Currently, there are 3 analysts who rate Tupperware Brands a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on TUP - FREE

TheStreet Quant Ratings rates Tupperware Brands as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Tupperware Brands Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Maximus (MMS) - FREE Research Report

Beliveau Russell A, who is Director at Maximus, sold 10,000 shares at $43.23 on May 14, 2014. Following this transaction, the Director owned 53,179 shares meaning that the stake was reduced by 15.83% with the 10,000-share transaction.

The shares most recently traded at $42.82, down $0.41, or 0.96% since the insider transaction. Historical insider transactions for Maximus go as follows:

  • 4-Week # shares sold: 4,290
  • 12-Week # shares sold: 45,294
  • 24-Week # shares sold: 216,264

The average volume for Maximus has been 394,900 shares per day over the past 30 days. Maximus has a market cap of $2.9 billion and is part of the services sector and diversified services industry. Shares are down 3.02% year-to-date as of the close of trading on Wednesday.

MAXIMUS, Inc. provides business process services to government health and human services agencies in the United States, Australia, Canada, the United Kingdom, and Saudi Arabia. The company operates in two segments, Health Services and Human Services. The stock currently has a dividend yield of 0.42%. The company has a P/E ratio of 21.7. Currently, there are 3 analysts who rate Maximus a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMS - FREE

TheStreet Quant Ratings rates Maximus as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Maximus Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Video: How to Select Mutual Funds in Your 401(k)

Video: How to Select Mutual Funds in Your 401(k)